Article

Interleukin-33 in asthma: how big of a role does it play?

Asthma and Allergic Disease Center, Box 801355, University of Virginia Health Systems, Charlottesville, VA 22908-1355, USA.
Current Allergy and Asthma Reports (Impact Factor: 2.45). 10/2010; 11(1):7-11. DOI: 10.1007/s11882-010-0153-8
Source: PubMed

ABSTRACT In complex disorders such as asthma and allergic disease, the goal for developing disease-modifying biotherapeutics is to find a target that is a central instigator of immunologic activity. Interleukin (IL)-33 seems to be such a molecule, as it is one of the earliest-released signaling molecules following epithelial damage and can orchestrate the recruitment and activation of the cells responsible for disease. Unregulated IL-33 activity leads to activation of T-helper type 2 cells, mast cells, dendritic cells, eosinophils, and basophils, ultimately leading to increased expression of cytokines and chemokines that define the disease. As such, IL-33 is an attractive candidate for therapeutic intervention with the goal of ameliorating disease. This review focuses on the role of IL-33 in promoting and maintaining the asthma phenotype.

Download full-text

Full-text

Available from: John W Steinke, Jun 21, 2015
1 Follower
 · 
80 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The pathogenesis of allergic asthma in childhood remains poorly understood. Environmental factors which appear to contribute to allergic sensitisation, with development of a Th2-biased immunological response in genetically predisposed individuals, include wheezing lower respiratory viral infections in early life and exposure to airborne environmental pollutants. These may activate pattern recognition receptors and/or cause oxidant injury to airway epithelial cells (AECs). In turn, this may promote Th2 polarisation via a "final common pathway" involving interaction between AEC, dendritic cells, and CD4+ T lymphocytes. Potentially important cytokines produced by AEC include thymic stromal lymphopoietin and interleukin-25. Their role is supported by in vitro studies using human AEC, as well as by experiments in animal models. To date, however, few investigations have employed models of the induction phase of childhood asthma. Further research may help to identify interventions that could reduce the risk of allergic asthma.
    Journal of Allergy 11/2011; 2011(1687-9783):257017. DOI:10.1155/2011/257017
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The incidence and severity of allergic asthma is rising, and novel strategies to prevent or treat this disease are needed. This study investigated the effects of different mixtures of non-digestible oligosaccharides combined with Bifidobacterium breve M-16V (BB) on the development of allergic airway inflammation in an animal model for house dust mite (HDM)-induced allergic asthma. BALB/c mice were sensitized intranasally (i.n.) with HDM and subsequently challenged (i.n.) with PBS or HDM while being fed diets containing different oligosaccharide mixtures in combination with BB or an isocaloric identical control diet. Bronchoalveolar lavage fluid (BALF) inflammatory cell influx, chemokine and cytokine concentrations in lung homogenates and supernatants of ex vivo HDM-restimulated lung cells were analyzed. The HDM-induced influx of eosinophils and lymphocytes was reduced by the diet containing the short-chain and long-chain fructo-oligosaccharides and BB (FFBB). In addition to the HDM-induced cell influx, concentrations of IL-33, CCL17, CCL22, IL-6, IL-13 and IL-5 were increased in supernatants of lung homogenates or BALF and IL-4, IFN-γ and IL-10 were increased in restimulated lung cell suspensions of HDM-allergic mice. The diet containing FFBB reduced IL-6, IFN-γ, IL-4 and IL-10 concentrations, whereas the combination of galacto-oligosaccharides and long-chain fructo-oligosaccharides with BB was less potent in this model. These findings show that synbiotic dietary supplementation can affect respiratory allergic inflammation induced by HDM. The combination of FFBB was most effective in the prevention of HDM-induced airway inflammation in mice.
    European Journal of Nutrition 05/2015; DOI:10.1007/s00394-015-0928-8 · 3.84 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The interleukin-33 (IL-33) has now emerged as a cytokine with diverse and pleiotropic functions in various infectious and inflammatory diseases. IL-33 is expressed by epithelial, endothelial cells, fibroblasts and hepatocytes. The target cells of IL-33 are the Th2 cells, basophils, dendritic cells, mast cells, macrophages, NKT cells and newly discovered nuocytes/natural helper cells/innate lymphoid cells bearing ST2 receptor. IL-33 has dual function both as a traditional cytokine and as a nuclear factor regulating gene transcription. IL-33 functions as an 'alarmin' released following cell death, as a biomarker, vaccine adjuvant, having pro-inflammatory and protective effects during various infections. The exacerbated or protective role of IL-33/ST2 axis during different infections is dependent upon the organ involved, type of infectious agent, acute or chronic infection, invasiveness of infectious agent, host immune compartment, cellular and cytokine microenvironment. In this review, we focus on the recent advances in understanding of the role of IL-33/ST2 axis in various viral, bacterial, fungal, helminth and protozoal infectious diseases in animal model and human patient studies. The functional role of IL-33 and ST2 during experimentally induced infections has been summarized by accumulating the data of IL-33 and ST2 deficient mice or exogenously administered IL-33. In summary exploring the crucial and diverse role of IL-33/ST2 axis during infections may help for therapeutic intervention across a wide range of infectious diseases. Copyright © 2015, American Society for Microbiology. All Rights Reserved.
    Infection and Immunity 02/2015; 83(5). DOI:10.1128/IAI.02908-14 · 4.16 Impact Factor